Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses sequencing challenges facing patients with renal cell carcinoma (RCC).
A sequencing challenge in the second-line setting is whether to start with a checkpoint antibody, such as nivolumab (Opdivo) or a multikianse inhibitor like cabozantinib (Cabometyx).
Nivolumab is well tolerated for the majority of patients who receive it. There is a subset of individuals who benefit from it. At this point in time, there are not good predictors of which agent should be given to which patient.